23Strands
Empowering women’s health globally with precision medicine
At a glance
-
Development stage
Active / generating revenue
-
Investment stage
Seed
-
UNSW affiliation
Founders startup
-
Technology readiness level
TRL-7
-
Female led
Yes
23Strands is a healthcare company using AI and genomics to deliver precision medicine for women’s health through a personalised, whole-of-life approach.
We address conditions including ovarian stimulation failure during IVF, endometriosis, PCOS, perimenopause, and breast cancer care. Our first go-to-market product, Fertility23, is a world-first solution for personalising and improving IVF success rates.
-
23Strands is a platform technology that uses AI to decode a patient's whole genome, creating a lifelong map for personalised healthcare, answering pharmacogenomic questions like “which medicine will be most effective for this patient?" 23Strands serves healthcare networks, pharmaceutical companies, and individuals through their doctors.
The company’s first focus is women's health. Fertility23 is a world-first collaboration to improve IVF success rates, providing critical answers to patients on their journey to start a family.
-
- For over 50% of women, ovarian stimulation during IVF treatment fails to produce the target number of eggs.
- Doctors have limited support, resources and tools in healthcare networks
- Pharma companies don't have the data they need to develop targeted therapies
-
- IVF and Obstetrics & Gynaecology clinic networks with an innovation focus are 23Strands’ first customers
- Pharmaceutical companies
- Direct to patient sales of diagnostic tests
-
- Secured first pharmaceutical customer with > AUD1.2 million revenue in FY25 (first year of sales)
- Industry partner on over AUD30 million non-dilutive grants across precision medicine & AI
- Raised >AUD5 million equity funding
Discover more UNSW spinouts
Search our catalogue of active spinouts and tech for license.